Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer

Cancer

Volumn 107, Issue 6, 2006, Pages 1321-1330

  Rojas, Ana M ^a   Lyn, Basil E ^a   Wilson, Elena M ^a   Williams, Frances J ^a   Shah, Nihal ^a   Dickson, Jeanette ^a   Saunders, Michele I ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

3 dimensional conformal radiotherapy; Accelerated radiotherapy week end less; Continuous; Early morbidity; Hyperfractionated; Late morbidity; Neoadjuvant chemotherapy; Nonsmall cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; IFOSFAMIDE; MITOMYCIN C; PACLITAXEL; TAXANE DERIVATIVE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSE CALCULATION; DRUG TREATMENT FAILURE; DYSPHAGIA; FEMALE; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEGLUTITION DISORDERS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKOCYTE COUNT; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PLATELET COUNT; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME;

EID: 33749006218     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22123     Document Type: Article

References (40)

1. Arriagada R, Le Chevalier T, Quoix E, et al. ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte Contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys. 1991;20:1183-1190.
2. Cox JD, Yesner RA. Causes of treatment failure and death in carcinoma of the lung. Yale J Biol Med. 1981;54:201-207.
3. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997;350:161-165.
4. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991;83:417-423.
5. Perez CA, Bauer M, Edelstein S, et al. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys. 1986;12:539-547.
6. Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonia's as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998;42:1-9.
7. Armstrong J, Raben A, Zelefsky M, et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol. 1997;44:17-22.
8. Patel RR, Mehta M. Three-dimensional conformal radiotherapy for lung cancer: promises and pitfalls. Curr Oncol Rep. 2002;4:347-353.
9. Saunders M, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering Committee. Radiother Oncol. 1999;52:137-148.
10. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899-909.
11. Saunders MI, Rojas A, Lyn BE, et al. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. J Clin Oncol. 2002;14:352-360.
12. Wilson EM, Williams FJ, Lyn BE, et al. Validation of active breathing control in patients with non-small-cell lung cancer to be treated with CHARTWEL. Int J Radiat Oncol Biol Phys. 2003;57:864-874.
13. International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon beam therapy (ICRU Report 50). Bethesda, MD: International Commission on Radiation Units and Measurements; 1993.
14. Dische S, Warburton MF, Jones D, et al. The recording of morbidity related to radiotherapy. Radiother Oncol. 1989;16:103-108.
15. Lee SW, Choi EK, Lee JS, et al. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003;56:996-1004.
16. Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of Stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a Phase I/II trial. Int J Radiat Oncol Biol Phys. 2002;54:348-356.
17. Sim S, Rosenzweig KE, Schindelheim R, et al. Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:660-665.
18. Bradley J, Movsas B. Radiation esophagitis: predictive factors and preventive strategies. Semin Radiat Oncol. 2004;14:280-286.
19. Byhardt RW. The evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 1995;32:1513-1525.
20. Byhardt RW, Scott C, Sause WT, et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1998;42:469-478.
21. Bentzen SM, Dorr W, Anscher MS, et al. Normal tissue effects: reporting and analysis. Semin Radiat Oncol. 2003;13:189-202.
22. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys. 2000;47:1-12.
23. Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol. 2004;22:19-22.
24. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45:323-329.
25. Graham MV, Purdy JA, Emami B, et al. Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 1995;33:993-1000.
26. Fowler JF, Chappell R. Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys. 2000;46:516-517.
27. Machtay M, Hsu C, Komaki R, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys. 2005;63:667-671.
28. Belderbos JS, De Jaeger K, Heemsbergen WD, et al. First results of a Phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol. 2003;66:119-126.
29. Maguire PD, Sibley GS, Zhou SM, et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys. 1999;45:97-103.
30. Bradley J, Graham MV Winter K, et al. Toxicity and outcome results of RTOG 9311: a Phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:318-328.
31. Marks LB, Garst J, Socinski MA, et al. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective Phase 1 dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol. 2004;22:4329-4340.
32. Rosenzweig KE, Fox JL, Yorke E, et al. Results of a Phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer. 2005;103:2118-2127.
33. Singh AK, Lockert MA, Bradley JD. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2003;55:337-341.
34. Socinski MA, Morris DE, Halle JS, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable Stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation Phase I trial. J Clin Oncol. 2004;22:4341-4350.
35. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable Stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I/II trial. Cancer. 2001;92:1213-1223.
36. Willner J, Schmidt M, Kirschner J, et al. Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol) and 3D-conformal radiotherapy of Stage III inoperable non-small cell lung cancer. Results of a dose escalation study. Lung Cancer. 2001;32:163-171.
37. Wolski MJ, Bhatnagar A, Flickinger JC, et al. Multivariate analysis of survival, local control, and time to distant metastases in patients with unresectable non-small-cell lung carcinoma treated with 3-dimensional conformal radiation therapy with or without concurrent chemotherapy. Clin Lung Cancer. 2005;7:100-106.
38. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/ unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:324-333.
39. Sibley GS, Mundt AJ, Shapiro C, et al. The treatment of Stage III nonsmall cell lung cancer using high dose conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1995;33:1001-1007.
40. Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2002;52:49-57.